1. PRODUCT AND COMPANY IDENTIFICATION

Product name: Lisinopril Formulation

Manufacturer or supplier’s details
Company: MSD
Address: 199 Wenhai North Road
HEDA, Hangzhou - Zhejiang Province - CHINA 310018
Telephone: 908-740-4000
Emergency telephone number: 86-571-87268110
E-mail address: EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use
Recommended use: Pharmaceutical

2. HAZARDS IDENTIFICATION

Emergency Overview

<table>
<thead>
<tr>
<th>Appearance</th>
<th>Colour</th>
<th>Odour</th>
<th>May damage the unborn child.</th>
</tr>
</thead>
<tbody>
<tr>
<td>powder</td>
<td>No data available</td>
<td>odourless</td>
<td></td>
</tr>
</tbody>
</table>

GHS Classification
Reproductive toxicity: Category 1A

GHS label elements
Hazard pictograms: 

Signal word: Danger

Hazard statements: H360D May damage the unborn child.

Precautionary statements
Prevention:
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:
P308 + P313 IF exposed or concerned: Get medical advice/
Lisinopril Formulation

Physical and chemical hazards
Not classified based on available information.

Health hazards
May damage the unborn child.

Environmental hazards
Not classified based on available information.

Other hazards which do not result in classification
Dust contact with the eyes can lead to mechanical irritation.
Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

3. COMPOSITION/INFORMATION ON INGREDIENTS

<table>
<thead>
<tr>
<th>Substance / Mixture</th>
<th>Composition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mixture</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Starch</td>
<td>9005-25-8</td>
<td>&gt;= 10 -&lt; 20</td>
</tr>
<tr>
<td>Lisinopril</td>
<td>83915-83-7</td>
<td>&gt;= 1 -&lt; 10</td>
</tr>
</tbody>
</table>

4. FIRST AID MEASURES

General advice
In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

If inhaled
If inhaled, remove to fresh air. Get medical attention.

In case of skin contact
In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact
If in eyes, rinse well with water. Get medical attention if irritation develops and persists.

If swallowed
If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

Most important symptoms and effects, both acute and
May damage the unborn child. Contact with dust can cause mechanical irritation or drying of
SAFETY DATA SHEET according to GB/T 16483 and GB/T 17519

Lisinopril Formulation

Version 2.9 Revision Date: 09/13/2019 SDS Number: 50013-00013 Date of last issue: 2018/10/16 Date of first issue: 2015/01/26

5. FIREFIGHTING MEASURES

Suitable extinguishing media: Water spray
Alcohol-resistant foam
Carbon dioxide (CO2)
Dry chemical

Unsuitable extinguishing media: None known.

Specific hazards during firefighting: Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.

Hazardous combustion products: Carbon oxides
Metal oxides
Oxides of phosphorus

Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures: Use personal protective equipment. Follow safe handling advice and personal protective equipment recommendations.

Environmental precautions: Discharge into the environment must be avoided. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spills cannot be contained.

Methods and materials for containment and cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items delayed the skin.

Dust contact with the eyes can lead to mechanical irritation.

Protection of first-aiders: First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

Notes to physician: Treat symptomatically and supportively.
employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

**Handling**

**Technical measures**: Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

**Local/Total ventilation**: If sufficient ventilation is unavailable, use with local exhaust ventilation.

**Advice on safe handling**:
- Do not get on skin or clothing.
- Do not breathe dust.
- Do not swallow.
- Avoid contact with eyes.
- Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
- Keep container tightly closed.
- Minimize dust generation and accumulation.
- Keep container closed when not in use.
- Keep away from heat and sources of ignition.
- Take precautionary measures against static discharges.
- Take care to prevent spills, waste and minimize release to the environment.

**Avoidance of contact**:
- Oxidizing agents

**Storage**

**Conditions for safe storage**:
- Keep in properly labelled containers.
- Store locked up.
- Keep tightly closed.
- Store in accordance with the particular national regulations.

**Materials to avoid**:
- Do not store with the following product types:
  - Strong oxidizing agents

**Packaging material**:
- Unsuitable material: None known.

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

**Components with workplace control parameters**

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters / Permissible concentration</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Starch</td>
<td>9005-25-8</td>
<td>TWA</td>
<td>10 mg/m³</td>
<td>ACGIH</td>
</tr>
<tr>
<td>Lisinopril</td>
<td>83915-83-7</td>
<td>TWA</td>
<td>40 µg/m³</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>400 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>

**Engineering measures**:
- Minimize workplace exposure concentrations.
SAFETY DATA SHEET  
according to GB/T 16483 and GB/T 17519  

Lisinopril Formulation  

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.9</td>
<td>09/13/2019</td>
<td>50013-00013</td>
<td>2018/10/16</td>
<td>2015/01/26</td>
</tr>
</tbody>
</table>

Apply measures to prevent dust explosions. Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment). If sufficient ventilation is unavailable, use with local exhaust ventilation.

**Personal protective equipment**

**Respiratory protection**: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

- **Filter type**: Particulates type
- **Eye/face protection**: Wear the following personal protective equipment: Safety goggles
- **Skin and body protection**: Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential. Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

**Hand protection**

- **Material**: Chemical-resistant gloves

**Remarks**: Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

**Hygiene measures**: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

### 9. PHYSICAL AND CHEMICAL PROPERTIES

- **Appearance**: powder
- **Colour**: No data available
- **Odour**: odourless
- **Odour Threshold**: No data available
- **pH**: No data available
- **Melting point/freezing point**: No data available
- **Initial boiling point and boiling**: No data available
SAFETY DATA SHEET
according to GB/T 16483 and GB/T 17519

Lisinopril Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.9</td>
<td>09/13/2019</td>
<td>50013-00013</td>
<td>2018/10/16</td>
<td>2015/01/26</td>
</tr>
</tbody>
</table>

- **Flash point**: No data available
- **Evaporation rate**: No data available
- **Flammability (solid, gas)**: May form explosive dust-air mixture during processing, handling or other means.
- **Flammability (liquids)**: No data available
- **Upper explosion limit / Upper flammability limit**: No data available
- **Lower explosion limit / Lower flammability limit**: No data available
- **Vapour pressure**: No data available
- **Relative vapour density**: No data available
- **Density**: No data available
- **Solubility(ies)**
  - **Water solubility**: No data available
- **Partition coefficient: n-octanol/water**: No data available
- **Auto-ignition temperature**: No data available
- **Decomposition temperature**: No data available
- **Viscosity**
  - **Viscosity, dynamic**: No data available
  - **Viscosity, kinematic**: No data available
- **Explosive properties**: Not explosive
- **Oxidizing properties**: The substance or mixture is not classified as oxidizing.
- **Molecular weight**: No data available
- **Particle size**: No data available

10. STABILITY AND REACTIVITY

- **Reactivity**: Not classified as a reactivity hazard.
- **Chemical stability**: Stable under normal conditions.
- **Possibility of hazardous reactions**: May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
Lisinopril Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>2.9</td>
<td>09/13/2019</td>
<td>50013-00013</td>
<td>2018/10/16</td>
<td>2015/01/26</td>
</tr>
</tbody>
</table>

Conditions to avoid: Heat, flames and sparks. Avoid dust formation.

Incompatible materials: Oxidizing agents

Hazardous decomposition products: No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Exposure routes:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Not classified based on available information.

Components:

Starch:
Acute oral toxicity: LD50 (Mouse): > 5,000 mg/kg

Lisinopril:
Acute oral toxicity: LD50 (Rat): > 20,000 mg/kg
LD50 (Mouse): > 20,000 mg/kg

Skin corrosion/irritation
Not classified based on available information.

Components:

Lisinopril:
Species: Rabbit
Result: Mild skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Lisinopril:
Species: Rabbit
Result: Mild eye irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.
Lisinopril Formulation

Components:

Lisinopril:

Test Type : Maximisation Test
Exposure routes : Dermal
Result : negative

Germ cell mutagenicity
Not classified based on available information.

Components:

Lisinopril:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster lung cells
Result: negative

Test Type: Alkaline elution assay
Test system: rat hepatocytes
Result: negative

Genotoxicity in vivo : Test Type: Micronucleus test
Species: Mouse
Application Route: Oral
Result: negative

Carcinogenicity
Not classified based on available information.

Components:

Lisinopril:

Species : Rat
Application Route : Oral
Exposure time : 105 weeks
NOAEL : 90 mg/kg body weight
Result : negative

Species : Mouse
Application Route : Oral
Exposure time : 92 weeks
NOAEL : 135 mg/kg body weight
Result : negative

Reproductive toxicity
May damage the unborn child.

Components:

Lisinopril:
Effects on fertility:
Test Type: Fertility
Species: Rat
Application Route: Oral
Fertility: NOAEL: 300 mg/kg body weight
Symptoms: No effects on mating performance
Result: Animal testing did not show any effects on fertility.

Effects on foetal development:
Test Type: Development
Species: Rat
Application Route: Oral
Developmental Toxicity: LOAEL: 30 mg/kg body weight
Result: positive, No teratogenic effects

Test Type: Development
Species: Mouse
Application Route: Oral
Developmental Toxicity: LOAEL: 100 mg/kg body weight
Symptoms: Total Resorptions / resorption rate
Result: Embryotoxic effects and adverse effects on the offspring were detected.

Test Type: Development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: LOAEL: 0.1 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected.

Reproductive toxicity - Assessment:
Positive evidence of adverse effects on development from human epidemiological studies.

STOT - single exposure:
Not classified based on available information.

STOT - repeated exposure:
Not classified based on available information.

Components:

Lisinopril:
Exposure routes: Ingestion
Target Organs: Kidney
Assessment: May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity:

Components:

Lisinopril:
Species: Rat
LOAEL: < 3,650 mg/kg
Application Route: Oral
Exposure time: 1 yr
Target Organs: Kidney
Species: Dog
LOAEL: < 840 mg/kg
Application Route: Oral
Exposure time: 4 Weeks
Target Organs: Kidney

Aspiration toxicity
Not classified based on available information.

Experience with human exposure

Components:

Lisinopril:
Ingestion:
Symptoms: Dizziness, Headache, Fatigue, Diarrhoea, Nausea, Cough, Lowered blood pressure, electrolyte imbalance
Remarks: May damage the unborn child.

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

Lisinopril:
Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 20,000 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

Persistence and degradability
No data available

Bioaccumulative potential
No data available

Mobility in soil
No data available

Other adverse effects
No data available

13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues: Dispose of in accordance with local regulations.
Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.
Lisinopril Formulation

14. TRANSPORT INFORMATION

**International Regulations**

**UNRTDG**
Not regulated as a dangerous good

**IATA-DGR**
Not regulated as a dangerous good

**IMDG-Code**
Not regulated as a dangerous good

**Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code**
Not applicable for product as supplied.

**National Regulations**

**GB 6944/12268**
Not regulated as a dangerous good

**Special precautions for user**
Not applicable

15. REGULATORY INFORMATION

**National regulatory information**

Law on the Prevention and Control of Occupational Diseases

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

**Further information**


Date format : yyyy/mm/dd

**Full text of other abbreviations**

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ACGIH / TWA : 8-hour, time-weighted average

AICS - Australian Inventory of Chemical Substances; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -
Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Disclaimer
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.